Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hypharm GmbH is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution for this portfolio is concentrated under 1 distinct examiner and 1 distinct art unit. This narrow scope indicates that the current patent activity is likely focused on a specific biological or pharmaceutical invention rather than a wide range of different technologies, requiring a specialized approach to navigating the assigned examiner's requirements.
MCKNIGHT, CIARA A is the busiest examiner for this entity, holding the 1 busiest examiner pending office action. Because there is only 1 distinct examiner assigned, the progress of the company's intellectual property depends entirely on the interactions with this single official. The involvement of 1 distinct art unit means that the legal strategy does not need to account for the differing examination cultures of multiple USPTO departments, allowing for a more streamlined but examiner-dependent approach to securing patent rights. This focus on 1 pending office action highlights the importance of understanding the specific technical preferences of the assigned reviewer.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCKNIGHT, CIARA A | 1 | 60.8% | +38.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17631221 | STABILIZING THERAPEUTIC PROTEINS WITH PIPERAZIN- OR MORPHOLINE-CONTAINING ZWITTERIONIC BUFFERING SUBSTANCES | MCKNIGHT, CIARA A | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17631221 | STABILIZING THERAPEUTIC PROTEINS WITH PIPERAZIN- OR MORPHOLINE-CONTAINING ZWITTERIONIC BUFFERING SUBSTANCES | MCKNIGHT, CIARA A | 1656 | §103 | Non-Final OA | — | Pending | Jan 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial